Common Stock, par value $0.0001 per share

BiomX Inc.

850 NEW BURTON ROAD, DOVER, DE, 19904

Items 5(a), (b), (c) and (e) of the Schedule 13D are hereby amended and restated in their entirety as follows: (1) Deerfield Mgmt V, L.P. Number of shares: 266,424 (comprised of shares of Common Stock and shares of Common Stock underlying warrants, in each case, held by Deerfield Private Design Fund V, L.P.) Percentage of Shares: 2.37%* (2) Deerfield Private Design Fund V, L.P. Number of shares: 266,424 (comprised of shares of Common Stock and shares of Common Stock underlying warrants,) Percentage of Shares: 2.37%* (3) Deerfield Mgmt HIF II, L.P., L.P. Number of shares: 266,424 (comprised of shares of Common Stock and shares of Common Stock underlying warrants, in each case, held by Deerfield Healthcare Innovations Fund II, L.P.) Percentage of Shares: 2.37%* (4) Deerfield Healthcare Innovations Fund II, L.P. Number of shares: 266,424 (comprised of shares of Common Stock and shares of Common Stock underlying warrants) Percentage of Shares: 2.37%* (5) Deerfield Management Number of shares: 533,370 (comprised of (i) shares of Common Stock and shares of Common Stock underlying warrants, in each case, held by Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P. and (ii) shares of Common Stock issuable upon exercise of options held by Jonathan Leff for the benefit, and at the direction, of Deerfield Management) Percentage of Shares: 4.70%* (6) Flynn Number of shares: 533,370 (comprised of (i) shares of Common Stock and shares of Common Stock underlying warrants, in each case, held by Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P. and (ii) shares of Common Stock issuable upon exercise of options held by Jonathan Leff for the benefit, and at the direction, of Deerfield Management) Percentage of Shares: 4.70%* *Throughout this report, the percentage of outstanding shares of Common Stock beneficially owned by the Reporting Persons reflects 11,160,153 shares of Common Stock outstanding as of June 2, 2026, as set forth in the Company's Definitive Proxy Statement on Schedule 14A filed by the Company with the Securities and Exchange Commission (the "SEC") on June 8, 2026. The number of shares of Common Stock beneficially owned by the Reporting Persons includes eighteen shares of Common Stock issued pursuant to the Funds' election to convert shares of Series X Preferred Stock into Common Stock on May 28, 2026 (in addition to the shares of Common Stock issued upon such conversion, as reported in Amendment No. 6 to the Schedule 13D), which eighteen shares were not reflected in Amendment No. 6 to the Schedule 13D due to a clerical error.

(1) Deerfield Mgmt V, L.P. Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 266,424 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 266,424 (2) Deerfield Private Design Fund V, L.P. Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 266,424 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 266,424 (3) Deerfield Mgmt HIF II, L.P. Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 266,424 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 266,424 (4) Deerfield Healthcare Innovations Fund II, L.P. Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 266,424 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 266,424 (5) Deerfield Management Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 533,370 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 533,370 (6) Flynn Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 533,370 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 533,370 Flynn is the sole manager of the general partner of each of Deerfield Mgmt V and Deerfield Mgmt HIF II and Deerfield Management. Deerfield Mgmt V is the general partner of Deerfield Private Design Fund V, L.P.; Deerfield Mgmt HIF II is the general partner of Deerfield Healthcare Innovations Fund II, L.P.; and Deerfield Management is the investment manager of each Fund. Each Fund purchases, holds and sells securities and other investment products. Schedule A hereto sets forth information regarding persons referred in Instruction C to Schedule 13D.

Transactions in the Common Stock effected by the Reporting Persons since the filing of Amendment No. 7 to the Schedule 13D are set forth on Exhibit 99.11 to this Amendment or disclosed in Item 3 to this Amendment. All transactions reflected in Exhibit 99.10 to this Amendment were effected in open market transactions on the Nasdaq Global Market in the ordinary course of the applicable Reporting Person's business.

As of June 16, 2026, the Reporting Persons ceased to beneficially own more than five percent of the Common Stock.